EGFR and squamous cell carcinoma: Another compound, Amlexanox, has been shown to bind S100A4, S100A12 and S100A13 [175,176] and to reduce proliferation of A431 epidermoid carcinoma cells by inhibiting S100A4 interaction with the Epidermal Growth Factor Receptor (EGFR) [176].